About the Special Issue

In the recent years, considerable advances have been achieved in understanding the inflammatory background of eosinophilic inflammation underlying respiratory and non-respiratory diseases. Severe eosinophilic asthma represents the most studied disease entity and several new biologics have been introduced as effective treatments. However, beyond severe asthma, eosinophilic inflammation plays pivotal role in other eosinophilic diseases as well, such as in eosinophilic granulomatosis with polyangiitis (EGPA), allergic bronchopulmonary aspergillosis, chronic eosinophilic pneumonia, nasal polyposis, hypereosinophilic syndrome, and eosinophilic esophagitis. Differences between asthma and other eosinophilic diseases, particularly in eosinophils homing, target organs and clinical features, probably account for the different response to treatment.  

This special issue focuses on eosinophilic biology, activity, signaling, and inflammatory process and discusses possible therapeutic targets. Furthermore, mechanisms of action, as well as efficacy and safety of the use of biologics beyond severe eosinophilic asthma, are discussed, covering diseases such as EGPA, allergic bronchopulmonary aspergillosis, chronic eosinophilic pneumonia, nasal polyposis, hypereosinophilic syndrome, and eosinophilic esophagitis. 

Keywords: Eosinophilic Inflammation, Severe Asthma, ABPA, EGPA, Eosinophilic Esophagitis, Mepolizumab, Reslizumab, Benralizumab.

Call for Papers